A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer (Q33383818)
scientific article
Language:
(P31) (Q13442814)
(P304) 2438-2446
(P407) (Q1860)
(P433) 11
(P478) 115
(P577) Monday, June 1, 2009
(P921) (Q181600)
(P1433) (Q326041)
(P1476) "A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer" (language: en)
(P2093) Robert J Amato
Jaroslaw Jac
Sarah Giessinger
Somyata Saxena
James P Willis
(P2860) (Q40482275)
(Q68815180)
(Q28282767)
(Q28282757)
(Q29618608)
(Q29618644)
(Q36692585)
(Q35990141)
(Q36623657)
(Q36623679)
(Q34010378)
(Q33323274)
(Q46708758)
(Q27860904)
(Q34293726)
(Q44551425)
(Q33379469)
(Q46803174)
(Q33360724)
(Q34542677)
(Q36250851)
(Q34317056)
(Q29618031)
other details
description scientific article

External Links